Drug Trial Radar · NCT06664801
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
164
Actual
Start
Nov 14, 2024
Primary completion
Nov 20, 2025
Study completion Nov 20, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. The goal of the study is to learn: * What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial. * About the safety of sotatercept and if people tolerate it
Conditions
- Pulmonary Arterial Hypertension
Interventions
SotaterceptBiological
SC administered every 3 weeks.
Background PAH TherapyBiological
Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists
Primary outcomes
What the sponsor says the trial is designed to measure.
- Steady-State Average Serum Concentrations of Sotatercept (Cavg)Time frame: Predose and at designated time points post-dose (up to 24 weeks)
- Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to 37 weeks
- Number of Participants who Discontinue Study Treatment due to an Adverse EventTime frame: Up to 21 weeks
Locations
98 sites in 21 countries. Site status is shown where the registry gives one.
Pulmonary Associates, PA ( Site 1903)
Phoenix, Arizona
University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 1930)
Aurora, Colorado
Indiana University Health Methodist Hospital ( Site 1905)
Indianapolis, Indiana
University of Kansas Medical Center ( Site 1928)
Kansas City, Kansas
Norton Pulmonary Specialists ( Site 1935)
Louisville, Kentucky
University of New Mexico Health Sciences Center - Department of Internal Medicine ( Site 1916)
Albuquerque, New Mexico
University of Cincinnati Medical Center ( Site 1927)
Cincinnati, Ohio
Ascension Seton Heart Specialty Care and Transplant Center ( Site 1918)
Austin, Texas
Froedtert Hospital & the Medical College of Wisconsin ( Site 1934)
Milwaukee, Wisconsin
Hospital Britanico de Buenos Aires ( Site 0004)
CABA, Argentina
Instituto de Cardiologia Juana F. Cabral ( Site 0008)
Corrientes, Argentina
Hospital Provincial Jose Maria Cullen ( Site 0005)
Santa Fe, Argentina
Centro Medico Capital ( Site 0002)
La Plata, Buenos Aires, Argentina
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0006)
Mar del Plata, Buenos Aires, Argentina
Instituto Medico Rio Cuarto ( Site 0010)
Río Cuarto, Córdoba Province, Argentina
Royal Prince Alfred Hospital ( Site 0103)
Camperdown, New South Wales, Australia
Westmead Hospital ( Site 0100)
Westmead, New South Wales, Australia
Wesley Research Institute ( Site 0101)
Auchenflower, Queensland, Australia
The Alfred Hospital ( Site 0102)
Melbourne, Victoria, Australia
Peter Lougheed Centre ( Site 0203)
Calgary, Alberta, Canada
IUCPQ ( Site 0208)
Québec, Quebec, Canada
Guangdong Provincial People s Hospital ( Site 2000)
Guangzhou, Guangdong, China
The Second Xiangya Hospital of Central South University ( Site 2002)
Changsha, Hunan, China
Shanghai Pulmonary Hospital ( Site 2004)
Shanghai, Shanghai Municipality, China
Yan an Hospital of Kunming City ( Site 2011)
Kunming, Yunnan, China
Clinica Cardio VID ( Site 0307)
Medellín, Antioquia, Colombia
Clinica Colsanitas - Sede Reina Sofia ( Site 0303)
Bogotá, Bogota D.C., Colombia
Fundacion Santa Fe de Bogota ( Site 0302)
Bogota, Cundinamarca, Colombia
IMAT S.A.S ( Site 0301)
Montería, Departamento de Córdoba, Colombia
Centro de Investigaciones Clinicas SAS ( Site 0306)
Cali, Valle del Cauca Department, Colombia
Clínica Imbanaco S.A.S ( Site 0304)
Cali, Valle del Cauca Department, Colombia
Centrum pro plicní hypertenzi VFN II. interni klinika VFN a 1. LF UK ( Site 0400)
Prague, Praha 2, Czechia
CHU Bordeaux Haut-Leveque ( Site 0501)
Pessac, Aquitaine, France
Assistance Publique Hôpitaux de Marseille - Hôpital Nord ( Site 0500)
Marseille, Bouches-du-Rhone, France
CHU Dijon Bourgogne ( Site 0502)
Dijon, Cote-d Or, France
CHU de Rouen ( Site 0503)
Rouen, Haute-Normandie, France
CHU GABRIEL MONTPIED ( Site 0504)
Clermont-Ferrand, Puy-de-Dome, France
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0609)
Berlin, Germany
Universitaetsklinikum Hamburg-Eppendorf ( Site 0610)
Hamburg, Germany
Thoraxklinik-Heidelberg gGmbH-Zentrum für Pulmonale Hypertonie ( Site 0600)
Heidelberg, Baden-Wurttemberg, Germany
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.